HUP9901186A2 - Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra - Google Patents

Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra

Info

Publication number
HUP9901186A2
HUP9901186A2 HU9901186A HUP9901186A HUP9901186A2 HU P9901186 A2 HUP9901186 A2 HU P9901186A2 HU 9901186 A HU9901186 A HU 9901186A HU P9901186 A HUP9901186 A HU P9901186A HU P9901186 A2 HUP9901186 A2 HU P9901186A2
Authority
HU
Hungary
Prior art keywords
protein
adjuvants
peptides
pharmaceutical composition
peptide
Prior art date
Application number
HU9901186A
Other languages
English (en)
Inventor
Max L. Birnstiel
Michael Buschle
Walter Schmidt
Tamás Schweighoffer
Peter Steinlein
Original Assignee
Boehringer Ingelheim International Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27215945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9901186(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Priority claimed from DE19638313A external-priority patent/DE19638313C2/de
Priority claimed from DE19648687A external-priority patent/DE19648687A1/de
Application filed by Boehringer Ingelheim International Gmbh. filed Critical Boehringer Ingelheim International Gmbh.
Publication of HUP9901186A2 publication Critical patent/HUP9901186A2/hu
Publication of HUP9901186A3 publication Critical patent/HUP9901186A3/hu
Publication of HU224410B1 publication Critical patent/HU224410B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

A találmány őlyan gyógyszerkészítményre vőnatkőzik, amely legalább egyimműnmődűlátőr hatású peptidet, fehérjét vagy fehérjefragmensttartalmaz egy adjűvánssal együtt, ahől az adjűváns azzal a képességgelrendelkezik, hőgy a peptid, illetőleg a fehérje vagy a fehérjefragmenskötődését a kezelendő egyén sejtjein, illetve a sejtekbe történőbelépését főkőzza, és ezáltal a peptid, illetve fehérje vagyfehérjefragmens imműnmődűlátőr hatásának felerősödését idézi elő. Atalálmány szerinti gyógyszerkészítmények tűmőrvakcinakéntalkalmazhatók. ŕ
HU9901186A 1996-02-24 1997-02-21 Peptid- és adjuvánsalapú gyógyszerkészítmény immunmodulációra HU224410B1 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19638313A DE19638313C2 (de) 1996-09-19 1996-09-19 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19648687A DE19648687A1 (de) 1996-11-25 1996-11-25 Pharmazeutische Zusammensetzung für die Immunmodulation
PCT/EP1997/000828 WO1997030721A1 (de) 1996-02-24 1997-02-21 Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien

Publications (3)

Publication Number Publication Date
HUP9901186A2 true HUP9901186A2 (hu) 1999-07-28
HUP9901186A3 HUP9901186A3 (en) 2001-01-29
HU224410B1 HU224410B1 (hu) 2005-08-29

Family

ID=27215945

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901186A HU224410B1 (hu) 1996-02-24 1997-02-21 Peptid- és adjuvánsalapú gyógyszerkészítmény immunmodulációra

Country Status (35)

Country Link
US (1) US7105162B1 (hu)
EP (1) EP0881906B2 (hu)
JP (1) JP4184433B2 (hu)
KR (1) KR100457647B1 (hu)
CN (1) CN1177610C (hu)
AR (1) AR005945A1 (hu)
AT (1) ATE274350T1 (hu)
AU (1) AU722264B2 (hu)
BG (1) BG63682B1 (hu)
BR (1) BR9707694A (hu)
CA (1) CA2243559C (hu)
CO (1) CO4600681A1 (hu)
CZ (1) CZ295396B6 (hu)
DE (1) DE59711873D1 (hu)
DK (1) DK0881906T4 (hu)
EE (1) EE04481B1 (hu)
ES (1) ES2225951T5 (hu)
HK (1) HK1017257A1 (hu)
HR (1) HRP970100B1 (hu)
HU (1) HU224410B1 (hu)
ID (1) ID16038A (hu)
IL (1) IL125361A (hu)
MY (1) MY119276A (hu)
NO (1) NO983850L (hu)
NZ (1) NZ332020A (hu)
PE (1) PE55398A1 (hu)
PL (1) PL189413B1 (hu)
PT (1) PT881906E (hu)
RO (1) RO119344B1 (hu)
RS (1) RS50101B (hu)
SI (1) SI0881906T2 (hu)
SK (1) SK284582B6 (hu)
TR (1) TR199801649T2 (hu)
TW (1) TW585774B (hu)
WO (1) WO1997030721A1 (hu)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
BR9908278A (pt) * 1998-02-25 2002-01-02 Iomai Corp Uso de agentes de melhoria de penetração e de rompimento de barreiras da pele, melhorar a resposta transcutânea imune induzida pela etoxina de ribosilatação de adp
ATE356620T1 (de) * 1998-04-20 2007-04-15 Torrey Pines Inst Topische immunostimulierung zur induzierung der migration der langerhanszellen
CA2362204C (en) * 1999-02-17 2011-11-08 John Cooper Cox Immunogenic complexes and methods relating thereto
DE19909503A1 (de) * 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT409762B (de) * 2000-04-13 2002-11-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung von zytokin sekretierenden zellen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
KR20020014459A (ko) * 2000-08-18 2002-02-25 서진호 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법
CA2433794A1 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
JP2004519453A (ja) * 2001-01-05 2004-07-02 インターツェル・アクチェンゲゼルシャフト ポリカチオン性化合物の用途
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
WO2003047602A1 (en) * 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
WO2004011650A2 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
WO2004035618A2 (en) 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
EP2287314A1 (en) 2003-03-04 2011-02-23 Intercell AG Streptococcus pyogenes antigens
DE602004029657D1 (de) 2003-03-24 2010-12-02 Intercell Ag Verbesserte impfstoffe
DE602004024179D1 (de) 2003-03-31 2009-12-31 Intercell Ag Staphylococcus epidermidis antigene
CA2522238A1 (en) 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
CN101864432A (zh) 2003-05-07 2010-10-20 英特塞尔股份公司 无乳链球菌抗原ⅰ和ⅱ
CA2525540A1 (en) 2003-05-30 2004-12-09 Intercell Ag Enterococcus antigens
CN1822856B (zh) 2003-07-11 2010-04-28 英特塞尔股份公司 Hcv疫苗
EP1987843A3 (en) 2004-03-12 2011-10-26 Intercell AG Method for solubilising peptide mixtures
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
EP1791858B1 (en) 2004-09-24 2010-04-21 Intercell AG Modified vp1-capsid protein of parvovirus b19
EP1804822B1 (en) * 2004-10-29 2009-07-22 Intercell AG Hcv vaccines for chronic hcv patients
WO2006112477A1 (ja) * 2005-04-20 2006-10-26 Taiho Pharmaceutical Co., Ltd. アジュバントとしてのポリアミノ酸
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
EP2287176A1 (en) 2006-09-15 2011-02-23 Intercell AG Borrelia antigens
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
EP2497779A1 (en) 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
KR100748265B1 (ko) * 2007-06-15 2007-08-10 (주)성문엔지니어링 공동주택에 배선된 전선의 합선방지구조
US20100203075A1 (en) 2007-06-18 2010-08-12 Intercell Ag Chlamydia antigens
PT2173376E (pt) 2007-08-02 2015-07-30 Biondvax Pharmaceuticals Ltd Vacinas de influenza multiepitópicas multiméricas
CA2719059C (en) * 2008-03-27 2016-05-17 Nestec S.A. Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates
US20110236470A1 (en) 2008-12-03 2011-09-29 Yaffa Mizrachi Nebenzahl GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
BR112012004276A2 (pt) * 2009-08-27 2017-10-24 Novartis Ag adjuvante compreendendo alumínio, oligonucleotídeo e policátion
WO2011057131A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Polysaccharide based hydrogels
NZ599527A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Fragmented hydrogels
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
RU2478399C2 (ru) * 2011-06-16 2013-04-10 Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) Способ получения специфического иммуномодулятора
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc A preparation containing at least two different complexes of purified stress protein linked to an antigenic peptide
US20190080044A1 (en) * 2016-03-15 2019-03-14 Repertoire Genesis Incorporation Monitoring and diagnosis for immunotherapy, and design for therapeutic agent
AU2017268822B2 (en) * 2016-05-27 2020-03-26 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
CN107469067B (zh) * 2017-09-05 2018-06-19 浙江大学 一种多肽及其改造体在制备免疫调节药物中的应用
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN110870912A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (hu) 1968-05-31 1972-09-20
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4728639A (en) * 1982-07-27 1988-03-01 University Of Tennessee Research Corporation Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
BE1000587A4 (fr) * 1986-06-13 1989-02-14 Oncogen Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.
DE68925660T2 (de) * 1988-06-10 1996-09-26 United Biomedical Inc Peptidfragmente von HIV
DE68927679T2 (de) * 1988-10-27 1997-06-26 Univ Minnesota Immunhilfsmittel aus Liposome enthaltend Lymphokin IL -2
WO1991009869A1 (en) 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP0636028B1 (en) 1992-04-03 2004-03-03 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising an amphiphatic cationic peptide
AU668772B2 (en) 1992-08-31 1996-05-16 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by HLA-A1, and uses thereof
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
CZ5191U1 (cs) * 1993-07-12 1996-09-12 Aliatros Medical, A.S. Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
UY24367A1 (es) † 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju

Also Published As

Publication number Publication date
WO1997030721A1 (de) 1997-08-28
CZ295396B6 (cs) 2005-08-17
SI0881906T1 (en) 2004-12-31
PL328455A1 (en) 1999-02-01
EE04481B1 (et) 2005-06-15
NO983850D0 (no) 1998-08-21
PE55398A1 (es) 1998-09-22
ATE274350T1 (de) 2004-09-15
EP0881906B2 (de) 2009-02-04
BR9707694A (pt) 1999-07-27
DE59711873D1 (de) 2004-09-30
KR100457647B1 (ko) 2005-06-20
DK0881906T4 (da) 2009-05-25
CA2243559A1 (en) 1997-08-28
BG102714A (en) 1999-06-30
SK114598A3 (en) 1999-06-11
CN1211926A (zh) 1999-03-24
ES2225951T5 (es) 2009-06-15
PT881906E (pt) 2004-10-29
HUP9901186A3 (en) 2001-01-29
AU722264B2 (en) 2000-07-27
PL189413B1 (pl) 2005-08-31
NO983850L (no) 1998-10-21
AR005945A1 (es) 1999-07-21
HU224410B1 (hu) 2005-08-29
HRP970100B1 (en) 2001-04-30
DK0881906T3 (da) 2004-12-20
TW585774B (en) 2004-05-01
IL125361A (en) 2002-08-14
TR199801649T2 (xx) 1998-12-21
US7105162B1 (en) 2006-09-12
RO119344B1 (ro) 2004-08-30
CN1177610C (zh) 2004-12-01
JP4184433B2 (ja) 2008-11-19
ID16038A (id) 1997-08-28
HK1017257A1 (en) 1999-11-19
CZ268998A3 (cs) 1999-07-14
CA2243559C (en) 2011-08-09
BG63682B1 (bg) 2002-09-30
EE9800255A (et) 1999-02-15
CO4600681A1 (es) 1998-05-08
JP2000506125A (ja) 2000-05-23
RS50101B (sr) 2009-01-22
HRP970100A2 (en) 1998-04-30
SK284582B6 (sk) 2005-07-01
ES2225951T3 (es) 2005-03-16
IL125361A0 (en) 1999-03-12
AU1875997A (en) 1997-09-10
YU6297A (sh) 1999-09-27
EP0881906A1 (de) 1998-12-09
MY119276A (en) 2005-04-30
KR19990082601A (ko) 1999-11-25
NZ332020A (en) 2000-02-28
EP0881906B1 (de) 2004-08-25
SI0881906T2 (sl) 2009-06-30

Similar Documents

Publication Publication Date Title
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
HK1043475A1 (en) Compositions and methods for treating infections using analogues of indolicidin
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DE3586853T2 (de) Immunologisch aktive Peptide, geeignet zur Einführung von Immunisierung gegen Malaria und deren Kodierung von Genen.
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
AU1463097A (en) Helicobacter pylori bacterioferritin
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
AU3426889A (en) Synthetic peptides from streptococcal m protein and vaccines prepared therefrom
DK0938329T3 (da) Immunogen TLP sammensætning
EP1174439A3 (en) Compositions and methods for treating infections using analogues of indolicidin
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
DE69928947D1 (de) Moraxella catarrhalis basb034 polypeptide und verwendungen davon
SE9600436D0 (sv) Vaccine against hantavirus
PT840750E (pt) Peptido antigenico de ha-2
BR0213554A (pt) Timosina para aumento da imunização genética
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050712

MM4A Lapse of definitive patent protection due to non-payment of fees